Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription


1 BMC Cancer
1 BMC Urol
2 Int J Urol
3 J Clin Oncol
1 J Nucl Med
2 Lancet Oncol
3 Oncogene
3 Oncol Rep
1 PLoS One
1 Urol Int

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BMC Cancer

  1. WONG SK, Hamm J, Shokoohi A, McGahan CE, et al
    Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.
    BMC Cancer. 2021;21:215.
    PubMed         Abstract available

    BMC Urol

  2. DERIGS M, Pehl A, Riera-Knorrenschild J, Hofmann R, et al
    Burkitt's lymphoma of the prostate presenting as acute urinary retention: a case report.
    BMC Urol. 2020;20:53.
    PubMed         Abstract available

    Int J Urol

  3. YOSHIDA S, Takahara T, Arita Y, Sakaino S, et al
    Whole-body diffusion-weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond.
    Int J Urol. 2021 Mar 6. doi: 10.1111/iju.14497.
    PubMed         Abstract available

  4. HATAKEYAMA S, Ohyama C
    Editorial Comment to Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database.
    Int J Urol. 2021 Mar 4. doi: 10.1111/iju.14539.

    J Clin Oncol

  5. JACKSON WC, Hartman HE, Dess RT, Spratt DE, et al
    Reply to L. C. Mendez et al and M. A. Kollmeier et al.
    J Clin Oncol. 2020;38:3823-3824.

  6. KOLLMEIER MA, McBride S, Gorovets D, Zelefsky MJ, et al
    Role of Androgen-Deprivation Therapy Remains Uncertain for Intermediate-Risk Patients When Using Dose-Escalated Radiotherapy.
    J Clin Oncol. 2020;38:3821-3822.

  7. DALLA VOLTA A, Mazziotti G, Maffezzoni F, Grisanti S, et al
    Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.
    J Clin Oncol. 2020;38:3363-3366.

    J Nucl Med

  8. BARATTO L, Song H, Duan H, Hatami N, et al
    PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2021 Mar 5. pii: jnumed.120.259630. doi: 10.2967/jnumed.120.259630.
    PubMed         Abstract available

    Lancet Oncol

  9. GHARZAI LA, Jiang R, Wallington D, Jones G, et al
    Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.
    Lancet Oncol. 2021;22:402-410.
    PubMed         Abstract available

  10. TREE AC, Dearnaley DP, Hall E
    Intermediate clinical endpoints in localised prostate cancer.
    Lancet Oncol. 2021;22:294-296.


  11. GALBRAITH LCA, Mui E, Nixon C, Hedley A, et al
    PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer.
    Oncogene. 2021 Mar 2. pii: 10.1038/s41388-021-01707.
    PubMed         Abstract available

  12. LEE HC, Ou CH, Huang YC, Hou PC, et al
    YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
    Oncogene. 2021 Mar 4. pii: 10.1038/s41388-021-01718.
    PubMed         Abstract available

  13. RIEDEL M, Berthelsen MF, Cai H, Haldrup J, et al
    In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun.
    Oncogene. 2021 Mar 5. pii: 10.1038/s41388-021-01724.
    PubMed         Abstract available

    Oncol Rep

  14. ZHU J, Qin P, Cao C, Dai G, et al
    Use of miR145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
    Oncol Rep. 2021;45:963-974.
    PubMed         Abstract available

  15. JI J, Shen T, Li Y, Liu Y, et al
    CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
    Oncol Rep. 2021;45:921-932.
    PubMed         Abstract available

  16. YANG Y, Liu T, Hu C, Xia H, et al
    Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castrationresistant prostate cancer.
    Oncol Rep. 2021;45:1.
    PubMed         Abstract available

    PLoS One

  17. GRAYSON KA, Jyotsana N, Ortiz-Otero N, King MR, et al
    Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes.
    PLoS One. 2021;16:e0246733.
    PubMed         Abstract available

    Urol Int

  18. BERG S, Hanske J, von Landenberg N, Noldus J, et al
    Institutional Adoption and Apprenticeship of Fusion Targeted Prostate Biopsy: Does Experience Affect the Cancer Detection Rate?
    Urol Int. 2020;104.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.